Biosensors: Raised its FY12 rev growth forecast to 50-60% from previous 20-30%, after completion of latest acq in JW Medical Systems despite it lowering ASPs for Drug-Eluting Stent Systems (DES) worldwide due to pricing pressures. Co est that China's DES mkt is around US$500m a yr and still growing...
Supported by the govt’s commitment to invest in the multi-year healthcare reform programme and inclusion of DES into it. Co suggests the market could grow larger than the US in the future. Stock currently trades at 26.7X P/E. DBSV has hold on stock with TP$1.40, OCBC has buy with TP$1.55
No comments:
Post a Comment